tbuckley/cabot-search huggingface dataset:
Case Management to Improve Uptake for Screening and Therapy of Hepatitis C viral infection in People Who Inject Drugs
Authors: Rob Bielen, Rita Verrando, Joris Penders, Els Oris, Frederik Nevens, Geert Robaeys
Journal: Hepatology (2016)

[Robaeys, Geert] Hasselt Univ, Fac Med & Life Sci, Tongeren, Belgium. [Bielen, Rob] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Verrando, Rita] Ctr Alcohol Andere Drugproblemen, Hasselt, Belgium. [Penders, Joris; Oris, Els] Ziekenhuis Oost Limburg, Dept Clin Biol, Genk, Belgium. [Nevens, Frederik] Univ Hosp KULeuven, Dept Gastroenterol & Hepatol, Leuven, Belgium. [Robaeys, Geert] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Genk, Belgium.
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
Authors: Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, John Adams, Curtis Triplitt, Ralph A. DeFronzo, Mahmoud Zirie, Amin Jayyousi
Journal: Diabetes Care (2017)

OBJECTIVE The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. RESEARCH DESIGN AND METHODS The study randomized 231 patients with poorly controlled (HbA1c &amp;gt;7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive 1) pioglitazone plus weekly exenatide (combination therapy) or 2) basal plus prandial insulin (insulin therapy) to maintain HbA1c &amp;lt;7.0% (53 mmol/mol). RESULTS After a mean follow-up of 12 months, combination therapy caused a robust decrease in HbA1c from 10.0 ± 0.6% (86 ± 5.2 mmol/mol) at baseline to 6.1 ± 0.1% (43 ± 0.7 mmol/mol) compared with 7.1 ± 0.1% (54 ± 0.8 mmol/mol) in subjects receiving insulin therapy. Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, BMI, or baseline HbA1c. Subjects in the insulin therapy group experienced significantly greater weight gain and a threefold higher rate of hypoglycemia than patients in the combination therapy group. CONCLUSIONS Combination exenatide/pioglitazone therapy is a very effective and safe therapeutic option in patients with long-standing poorly controlled T2DM on metformin plus a sulfonylurea.
Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation
Authors: Julia Cadrin-Tourigny, Azadeh Shohoudi, Denis Roy, Mario Talajic, Rafik Tadros, Blandine Mondésert, Katia Dyrda, Léna Rivard, Jason G. Andrade, Laurent Macle, Peter G. Guerra, Bernard Thibault, Marc Dubuc, Paul Khairy
Journal: JACC Heart Failure (2017)
Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study
Authors: Phoenix A. Ho, Todd A. Alonzo, Kenneth J. Kopecky, Kristen L. Miller, Julia Kuhn, Rong Zeng, Rhonda E. Ries, Robert B. Gerbing, Wenhong Fan, Susana C. Raimondi, Betsy A. Hirsch, Vivian Oehler, Craig A. Hurwitz, Janet Franklin, Alan S. Gamis, Stephen H. Petersdorf, Jeanne E. Anderson, John E. Godwin, Gregory H. Reaman, Cheryl L. Willman, Lue Ping Zhao, Irwin D. Bernstein, Jerald P. Radich, Frederick R. Appelbaum, Derek L. Stirewalt, Soheil Meshinchi
Journal: Blood (2010)
Transfusions of Red Blood Cells Stored for 40–42 Days Induce Circulating Non-Transferrin-Bound Iron (NTBI) In Healthy Adults
Authors: Eldad A. Hod, Gary M. Brittenham, Genia B. Billote, Yelena Ginzburg, Shruti Sharma, Boguslaw S. Wojczyk, Richard O. Francis, Brie A. Stotler, Anthony Sireci, Hannah L. Stephens, Joseph Schwartz, Gordana Olbina, Mark Westerman, Sujit Sheth, Steven L. Spitalnik
Journal: Blood (2010)
Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study
Authors: Meir Wetzler, Jessica Kohlschmidt, Krzysztof Mrózek, Herve Dombret, Hartmut Döhner, Sylvain Pilorge, Utz Krug, Richard A. Larson, Guido Marcucci, Wolfgang Hiddemann, Thomas Buchner, Clara D. Bloomfield
Journal: Blood (2011)
Results with ATRA and Anthracycline Based Chemotherapy (CT) in Acute Promyelocytic Leukemia (APL) in a Developing Country. Should Dose Intensity Be Reduced to Obtain Acceptable Results?
Authors: Ramzi Jeddi, Hèla Ghédira, Hèla Stambouli, Ramzi Ben amor, Karima Kacem, Yosr Ben Abdennebi, Mohamed Zarrouk, Hend Ben Neji, Raihane ben Lakhal, Lamia Aissaoui, Samia Menif, Emna Gouider, Hèla Ben Abid, Zaher Ben Hadjali, Pierre Fenaux, Balkis Meddeb
Journal: Blood (2011)
Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease
Authors: Monika A. Niewczas, Anna V. Mathew, Stephanie Croall, Jaeman Byun, Melissa Major, Venkatta S. Sabisetti, Adam Smiles, Joseph V. Bonventre, Subramaniam Pennathur, Andrzej S. Krolewski
Journal: Diabetes Care (2017)

Patients with type 1 diabetes (T1D) with impaired renal function are at increased risk for end-stage renal disease (ESRD). Although the rate of progression varies, determinants and mechanisms of this variation are unknown.We examined serum metabolomic profiles associated with variation in renal function decline in participants with T1D (the Joslin Kidney Study prospective cohort). One hundred fifty-eight patients with proteinuria and chronic kidney disease stage 3 were followed for a median of 11 years to determine estimated glomerular filtration rate slopes from serial measurements of serum creatinine and to ascertain time to onset of ESRD. Baseline serum samples were subjected to global metabolomic profiling.One hundred ten amino acids and purine and pyrimidine metabolites were detected in at least 80% of participants. Serum levels of seven modified metabolites (C-glycosyltryptophan, pseudouridine, O-sulfotyrosine, N-acetylthreonine, N-acetylserine, N6-carbamoylthreonyladenosine, and N6-acetyllysine) were associated with renal function decline and time to ESRD (P < 0.001) independent of the relevant clinical covariates. The significant metabolites correlated with one another and with the indices of tubular injury.This prospective cohort study in participants with T1D, proteinuria, and impaired renal function at baseline demonstrated that patients with increased circulating levels of certain modified metabolites experience faster renal function decline, leading to ESRD. Whether some of these candidate metabolites are risk factors or just prognostic biomarkers of progression to ESRD in T1D needs to be determined.
Photoacoustic Imaging: Protein‐Modified CuS Nanotriangles: A Potential Multimodal Nanoplatform for In Vivo Tumor Photoacoustic/Magnetic Resonance Dual‐Modal Imaging (Adv. Healthcare Mater. 1/2017)
Authors: Duyang Gao, Zonghai Sheng, Yubin Liu, Dehong Hu, Jian Zhang, Xuanjun Zhang, Hairong Zheng, Zhen Yuan
Journal: Advanced Healthcare Materials (2017)

Hairong Zheng, Zhen Yuan, and co-workers design a general method to prepare multimodal nanoprobes based on protein-modified CuS nanotriangles which can conjugate with functional blocks using abundant reaction groups of protein in article 1601094. Diethylenetriaminepentaacetic acid-Gd3+ is linked on the platform to prove the idea, the as-prepared nanoprobe is successfully used for in vivo photoacoustic/magnetic resonance dual-modal tumor imaging.
Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.
Authors: Roland Jäger, Heinz Gisslinger, Tiina Berg, Francesco Passamonti, Mario Cazzola, Elisa Rumi, Daniela Pietra, Bettina Gisslinger, Thorsten Klampfl, Ashot Harutyunyan, Damla Olcaydu, Robert Kralovics
Journal: Blood (2009)
Clinical Scoring, the PF4 ENHANCED Assay, and the 14 C-Serotinin Release Assay for the Diagnosis of Heparin Induced Thrombocytopenia (HIT) in Complex Medical and Surgical Patients.
Authors: Gurvinder Shaheed, Vera Malkovska, McDonald Horne, Jose Mendoza, Mehool Patel, John Rees, Robert Wesley, Paula Merryman
Journal: Blood (2006)
Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study
Authors: Jeffrey A. Barnes, Robert Allyn Redd, Eric D. Jacobsen, David C. Fisher, Arnold S. Freedman, Ephraim P Hochberg, Tak Takvorian, Donna Neuberg, Jeremy S. Abramson
Journal: Blood (2014)
Microarray Analysis Detects Unique Expression Pattern for NPM1-Mutated AML with Normal Karyotype and Reveals Pathobiological Insights.
Authors: Torsten Haferlach, Claudia Haferlach, Alexander Kohlmann, Lothar Wieczorek, Martin Dugas, Sylvia Merk, Wolfgang Kern, Susanne Schnittger
Journal: Blood (2007)
Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models
Authors: Dianna M. Milewicz, Siddharth K. Prakash, Francesco Ramirez
Journal: Annual Review of Medicine (2017)

Thoracic aortic diseases, including aneurysms and dissections of the thoracic aorta, are a major cause of morbidity and mortality. Risk factors for thoracic aortic disease include increased hemodynamic forces on the ascending aorta, typically due to poorly controlled hypertension, and heritable genetic variants. The altered genes predisposing to thoracic aortic disease either disrupt smooth muscle cell (SMC) contraction or adherence to an impaired extracellular matrix, or decrease canonical transforming growth factor beta (TGF-β) signaling. Paradoxically, TGF-β hyperactivity has been postulated to be the primary driver for the disease. More recently, it has been proposed that the response of aortic SMCs to the hemodynamic load on a structurally defective aorta is the primary driver of thoracic aortic disease, and that TGF-β overactivity in diseased aortas is a secondary, unproductive response to restore tissue function. The engineering of mouse models of inherited aortopathies has identified potential therapeutic agents to prevent thoracic aortic disease.
ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 Performance Measures for Adults With Peripheral Artery Disease
Authors: Jeffrey W. Olin, David E. Allie, Michael Belkin, Robert O. Bonow, Donald E. Casey, Mark A. Creager, Thomas C. Gerber, Alan T. Hirsch, Michael R. Jaff, John A. Kaufman, Curtis A. Lewis, Edward T. Martin, Louis G. Martin, Peter Sheehan, Kerry J. Stewart, Diane Treat-Jacobson, Christopher J. White, Zhi-Jie Zheng
Journal: Circulation (2010)
Genetic Determinants of Hemolysis in Sickle Cell Anemia.
Authors: Jacqueline N Milton, Helen Rooks, Emma Drasar, Elizabeth L McCabe, Clinton T. Baldwin, Efthymia Melista, Victor R. Gordeuk, Mehdi Nouraie, Gregory J. Kato, Caterina Minniti, James G. Taylor, Andrew Campbell, Lori Luchtman-Jones, Sohail R. Rana, Oswaldo L Castro, Yingze Zhang, Swee Lay Thein, Mark T Gladwin, Paola Sebastiani, Martin H. Steinberg
Journal: Blood (2012)
Peter Gordon Gaskell
Authors: Philip Gaskell
Journal: BMJ (2017)

After being medically discharged from the infantry, Peter Gordon Gaskell entered medical school at Glasgow University in 1944. He undertook what at the time was eccentric postgraduate training—a first house job in obstetrics and gynaecology and then a rotating house job, both in Glasgow. He was assistant in general practice in west Cumberland, six months as acting medical registrar in Ayrshire, and two years as a senior house officer in Inverness in the first ever combined training scheme in hospital and general practice, an account of which was published. This was followed by seven years as a singlehanded …
<i>Campylobacter jejuni</i>transducer like proteins: Chemotaxis and beyond
Authors: Kshipra Chandrashekhar, Issmat I. Kassem, Gireesh Rajashekara
Journal: Gut Microbes (2017)

Chemotaxis, a process that mediates directional motility toward or away from chemical stimuli (chemoeffectors/ligands that can be attractants or repellents) in the environment, plays an important role in the adaptation of Campylobacter jejuni to disparate niches. The chemotaxis system consists of core signal transduction proteins and methyl-accepting-domain-containing Transducer like proteins (Tlps). Ligands binding to Tlps relay a signal to chemotaxis proteins in the cytoplasm which initiate a signal transduction cascade, culminating into a directional flagellar movement. Tlps facilitate substrate-specific chemotaxis in C. jejuni, which plays an important role in the pathogen's adaptation, pathobiology and colonization of the chicken gastrointestinal tract. However, the role of Tlps in C. jejuni's host tissue specific colonization, physiology and virulence remains not completely understood. Based on recent studies, it can be predicted that Tlps might be important targets for developing strategies to control C. jejuni via vaccines and antimicrobials.
Effect of Melphalan 140 Mg/m2 Versus 200 Mg/m2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation
Authors: Lakshmikanth Katragadda, Lindsay McCullough, Yunfeng Dai, Jack W Hsu, John W Hiemenz, W. Stratford May, Christopher R. Cogle, Maxim Norkin, Randy A Brown, John R. Wingard, Myron Chang, Jan S Moreb
Journal: Blood (2015)
Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic
Authors: John P. Middleton, Myles Wolf
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)
Authors: Dirk Winkler, Raymonde Busch, Andreas Buehler, Michael K. Wenger, Kirsten Fischer, Anna-Maria Fink, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2011)
Fast and Non-Invasive Identification of Tumorigenic-Proliferative Biomarker in Myeloproliferative and Lymphoproliferative Disorders
Authors: Iolanda Donatella Vincelli, Bruno Martino, Maria Cuzzola, Giuseppe Irrera, Patrizia Cufari, Massimo Martino, Massimo Gentile, Stefania Ciolli, AnnaMaria Zaccuri, Daniela Pontoriero, Carmela Rigolino, Angela Violi, Francesca Ronco
Journal: Blood (2015)
Unmanipulated Bone Marrow Transplantation From Haploidentical Related Donor for Patients with High-Risk Hematological Malignancies
Authors: Paolo Di Bartolomeo, Stella Santarone, Gottardo De Angelis, Alessandra Picardi, Pasqua Bavaro, Erminia Di Bartolomeo, Paola Olioso, Marta Di Nicola, Lidia De Felice, Laura Cudillo, Raffaella Cerretti, William Arcese
Journal: Blood (2010)
Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014
Authors: Bożena Walewska-Zielecka, Urszula Religioni, Grzegorz Juszczyk, Zbigniew M Wawrzyniak, Aleksandra Czerw, Piotr Soszyński, Adam Fronczak
Journal: Eurosurveillance (2017)

Hepatitis C virus (HCV) infection is considered by the World Health Organization (WHO) to be a serious public health concern and one of the major public health priorities. In 2005, it was estimated that there are 185 million anti-HCV positive people in the world, which constitutes 2.8% of the global population. Our study estimates the anti-HCV seroprevalence in the working age population (15-64 years-old), mostly urban and suburban residents, in Poland from 2004 to 2014. The studied group consisted of 61,805 working-age population representatives whose data were obtained from electronic medical records of an outpatient clinic network operating on a countrywide level. Positive anti-HCV test results were obtained in 957 patients, representing 1.5% of the whole population studied throughout the analysed period. The average age of all anti-HCV positive patients was 36.8 years. Analysis of the data suggests that the proportion of anti-HCV positive patients decreased over the study period (mean positive anti-HCV = -0.0017 × year + 3.3715; R2 = 0.7558). In 2004, positive results were noted among 3.2% of patients undergoing HCV antibody tests, but in 2014, the percentage of patients with a positive result stood at 1.1%. The apparent decrease affected men and women similarly. Our study also provides evidence that screening people born before 1965 could be beneficial.
Use of preoperative liver biopsy to predict livers that have avoided chemotherapy-induced liver injury.
Authors: J. Belghiti, L. Genser, D. Fuks, S. Dokmak, S. J. Faivre, V. Paradis
Journal: Journal of Clinical Oncology (2011)

393 Background: Liver parenchymal damage caused by neoadjuvant chemotherapy may increase the surgical risk. The aim of the present study was to assess the performance of preoperative liver biopsy (PLB) in predicting the status of the liver parenchyma at the time of resection. Methods: Among 40 patients who underwent liver resection after neoadjuvant chemotherapy for colorectal liver metastases (CLM) in 2009, 28 had percutaneous PLB from 2 to 6 weeks after onset of the treatment. Patients underwent a mean number of 9 cycles of chemotherapy (range 4-22). Chemotherapy included oxaliplatin (n=22), irinotecan (n=10), and bevacizumab (n=12). PLB and surgical specimens were compared according to the presence and rate of steatosis, sinusoidal obstruction syndrome (SOS) and chemotherapy-associated steatohepatitis (CASH). Results: Surgical specimen analysis showed steatosis in 12 (43%) patients (ranging from 5 to 80%), SOS in 12 patients (43%) and CASH in 1 patient (3%). The sensitivity, specificity, positive predictive value and negative predictive value of PLB for steatosis were 67%, 81%, 73% and 77%, respectively. It was 50%, 94%, 86% and 71%, respectively for SOS and 0%, 100%, 0% and 96%, respectively for CASH. Performance of PLB was not related to the type of chemotherapy. Among the 28 patients, 8 patients had no abnormalities on PLB. In 7 of them, surgical specimen analysis was considered normal. Conclusions: The accuracy of PLB in predicting chemotherapy- induced liver injury appears to be low. It is useful, however, given its high specificity when the PBL is normal, for encouraging hepatic resection without delay. No significant financial relationships to disclose.
How to prevent the microvascular complications of type 2 diabetes beyond glucose control
Authors: Willy Marcos Valencia, Hermes Florez
Journal: BMJ (2017)

Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society. If left uncontrolled or untreated, they lead to irreversible damage and even death. This review focuses on the primary and secondary prevention of diabetic microvascular complications in patients with type 2 diabetes, beyond glycemic control. Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. High level evidence sources such as systematic reviews and large, multicenter randomized clinical trials have been prioritized. Smaller trials were included where high quality evidence was unavailable.
Comparative Analysis of CD8+ t Cell Priming Efficiencies against a Panel of Leukemia-Associated HLA-A2 Restricted Epitopes Identifies PRAME as a Possible Vaccination Target in AML
Authors: Willemijn van den Ancker, Theresia M Westers, Hetty J Bontkes, Erik Hooijberg, Anita GM Stam, Saskia JAM Santegoets, Gert J Ossenkoppele, Tanja D de Gruijl, Arjan A van de Loosdrecht
Journal: Blood (2008)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Authors: Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
Journal: Annals of the Rheumatic Diseases (2017)

To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.
Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).
Authors: Pankaj Malhotra, William J. Hogan, Mark R. Litzow, Michelle A. Elliott, Angela Dispenzieri, Timothy Call, Neil E. Kay, Clive Zent, Dennis A. Gastineau, Steven M. Ansell, Suzanne Hayman, Morie A. Gertz, Martha Q. Lacy, Luis F. Porrata, David J. Inwards, Ayalew Tefferi
Journal: Blood (2005)